TrialSignal transduction and targeted therapy2023

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study.

Tian-Qi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.